Clinical Trial Update: A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) [Phase 3]

View source ↗

Summary

Phase 3 long-term study of LY3074828 in moderate-to-severe plaque psoriasis was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• LY3074828

Snippet

Sponsor: Eli Lilly and Company | Conditions: Psoriasis | Phase 3 | Status: TERMINATED | Results posted: 2023-03-21